From Heart Failure to Holistic Cardiac: CardioScope AI-ECG Platform

The CardioScope project harnesses artificial intelligence (AI)-enabled electrocardiography (ECG) as a scalable digital biomarker for the early detection of left ventricular systolic dysfunction, a clinically silent precursor to heart failure that is often recognized only after irreversible myocardial damage has developed. This dysfunction usually requires echocardiography for detection, but echocardiography is expensive, requires specialized personnel, and is constrained by equipment availability. In contrast, ECGs are easily accessible, low cost and rapid in acquisition, allowing for efficient population-level screening and early therapeutic intervention.

We have developed a deep-learning model embedded within a secure, clinician-facing software platform. Through the development and rigorous multi-center validation of CardioScope, we will deliver real-time, non-invasive decision support that reduces diagnostic delays, optimizes healthcare resource utilization, and improves patient outcomes. Beyond heart failure prevention, the platform is establishing a flexible digital biomarker engine with the potential to expand across cardiovascular and systemic diseases, positioning it as a cornerstone for precision medicine, national AI health innovation, and cost-effective large-scale screening.